Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR

Journal of Endocrinological Investigation

Volumn 28, Issue 4, 2005, Pages 166-169

  Resmini, E ^a   Murialdo, G ^a   Giusti, M ^a   Boschetti, M ^a   Minuto, F ^a   Ferone, D ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Acromegaly; Magnetic resonance imaging; Octreotide; Pituitary tumors

Indexed keywords

OCTREOTIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ACROMEGALY; AGED; ANAMNESIS; ARTICLE; CANCER REGRESSION; CASE REPORT; DOSE RESPONSE; ECHOGRAPHY; ENDOCRINE FUNCTION TEST; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM SEPTUM DEFECT; HEART BUNDLE BRANCH BLOCK; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIMETRY; ADENOMA; DELAYED RELEASE FORMULATION; FOLLOW UP;

ACROMEGALY; ADENOMA; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; OCTREOTIDE; PITUITARY NEOPLASMS;

EID: 20444436814     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03345361     Document Type: Article

References (14)

1. Daughaday WH, Mariz IK, Blethen SL. Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum. J Clin Endocrinol Metab 1980, 51: 781-8.
2. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526-9.
3. Ferone D, Colao A, van der Lely AJ, Lamberts SW. Pharmacotherapy or surgery as primary treatment for acromegaly? Drugs Aging 2000, 17: 81-92.
4. Van der Lely AJ, Muller A, Janssen JA, et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab. 2001, 86: 478-81.
5. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002, 87: 4554-63.
6. Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001, 86: 2779-86.
7. Amato G, Mazziotti G, Rotondi M, et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 2002, 56: 65-71.
8. Minuto F, Resmini E, Boschetti M, et al. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system. Clin Endocrinol (Oxf) 2004, 61: 138-44.
9. Mangupli R, Lisette A, Ivett C, et al. Improvement of acromegaly after octreotide LAR treatment. Pituitary 2003, 6: 29-34.
10. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102-52.
11. McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 2003, 63: 2473-99.
12. Paisley AN, Trainer PJ. Medical treatment in acromegaly. Curr Opin Pharmacol 2003, 3: 672-7.
13. Nakauchi Y, Kumon Y, Yamasaki H, Tahara K, Kurisaka M, Hashimoto K. Scalp hair loss caused by octreotide in a patient with acromegaly: a case report. Endocr J 1995, 42: 385-9.
14. Lami MC, Hadjadj S, Guillet G. Hair loss in three patients with acromegaly treated with octreotide. Br J Dermatol 2003, 149: 655-6.